JP2003514020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514020A5 JP2003514020A5 JP2001537954A JP2001537954A JP2003514020A5 JP 2003514020 A5 JP2003514020 A5 JP 2003514020A5 JP 2001537954 A JP2001537954 A JP 2001537954A JP 2001537954 A JP2001537954 A JP 2001537954A JP 2003514020 A5 JP2003514020 A5 JP 2003514020A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrosated
- antioxidant
- hydralazine
- administering
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 80
- 239000003963 antioxidant agent Substances 0.000 description 34
- 230000003078 antioxidant effect Effects 0.000 description 33
- 235000006708 antioxidants Nutrition 0.000 description 27
- RPTUSVTUFVMDQK-UHFFFAOYSA-N hydrallazine Natural products C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 22
- 229960002474 hydralazine Drugs 0.000 description 19
- -1 hydralazine compound Chemical class 0.000 description 19
- 229960000201 isosorbide dinitrate Drugs 0.000 description 19
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 19
- 229960003827 isosorbide mononitrate Drugs 0.000 description 19
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 13
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 12
- 239000005541 ACE inhibitor Substances 0.000 description 9
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 9
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 9
- 229940127291 Calcium channel antagonist Drugs 0.000 description 9
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 9
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 9
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 9
- 239000000480 calcium channel blocker Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000002308 endothelin receptor antagonist Substances 0.000 description 9
- 239000002461 renin inhibitor Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000002876 beta blocker Substances 0.000 description 8
- 235000017471 coenzyme Q10 Nutrition 0.000 description 8
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 229940086526 renin-inhibitors Drugs 0.000 description 8
- 150000003384 small molecules Chemical group 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000012730 sustained-release form Substances 0.000 description 7
- 102100028255 Renin Human genes 0.000 description 6
- 108090000783 Renin Proteins 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 208000019553 vascular disease Diseases 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 4
- 108010053835 Catalase Proteins 0.000 description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- 102000006587 Glutathione peroxidase Human genes 0.000 description 4
- 108700016172 Glutathione peroxidases Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 229960002433 cysteine Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 4
- 229940035936 ubiquinone Drugs 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- QLTVVOATEHFXLT-UHFFFAOYSA-N Cadralazine Chemical compound CCOC(=O)NNC1=CC=C(N(CC)CC(C)O)N=N1 QLTVVOATEHFXLT-UHFFFAOYSA-N 0.000 description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 description 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 3
- 206010070538 Gestational hypertension Diseases 0.000 description 3
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 3
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 3
- 229950001730 budralazine Drugs 0.000 description 3
- DQGFCLJXYFXXIJ-LFIBNONCSA-N budralazine Chemical compound C1=CC=C2C(N/N=C(C)/C=C(C)C)=NN=CC2=C1 DQGFCLJXYFXXIJ-LFIBNONCSA-N 0.000 description 3
- 229960005211 cadralazine Drugs 0.000 description 3
- 229940068682 chewable tablet Drugs 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 229960002877 dihydralazine Drugs 0.000 description 3
- VQKLRVZQQYVIJW-UHFFFAOYSA-N dihydralazine Chemical compound C1=CC=C2C(NN)=NN=C(NN)C2=C1 VQKLRVZQQYVIJW-UHFFFAOYSA-N 0.000 description 3
- 229960002029 endralazine Drugs 0.000 description 3
- ALAXZYHFVBSJKZ-UHFFFAOYSA-N endralazine Chemical compound C1CC=2N=NC(NN)=CC=2CN1C(=O)C1=CC=CC=C1 ALAXZYHFVBSJKZ-UHFFFAOYSA-N 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 239000006190 sub-lingual tablet Substances 0.000 description 3
- 229940098466 sublingual tablet Drugs 0.000 description 3
- 230000009424 thromboembolic effect Effects 0.000 description 3
- 229950001089 todralazine Drugs 0.000 description 3
- IOBPWVWEMXSDBY-AWEZNQCLSA-N (3s)-4-oxo-3-[[6-[[[3-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]sulfonylamino]methyl]pyridine-3-carbonyl]amino]butanoic acid Chemical compound N1=CC(C(=O)N[C@@H](CC(=O)O)C=O)=CC=C1CNS(=O)(=O)C1=CC=CC(C=2NOC(=O)N=2)=C1 IOBPWVWEMXSDBY-AWEZNQCLSA-N 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003782 Raynaud disease Diseases 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16223099P | 1999-10-29 | 1999-10-29 | |
| US60/162,230 | 1999-10-29 | ||
| US17902000P | 2000-01-31 | 2000-01-31 | |
| US60/179,020 | 2000-01-31 | ||
| PCT/US2000/029528 WO2001035961A1 (en) | 1999-10-29 | 2000-10-27 | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514020A JP2003514020A (ja) | 2003-04-15 |
| JP2003514020A5 true JP2003514020A5 (https=) | 2007-07-19 |
Family
ID=26858558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001537954A Pending JP2003514020A (ja) | 1999-10-29 | 2000-10-27 | 酸化窒素不足により特徴付けられる血管疾患の治療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6635273B1 (https=) |
| EP (1) | EP1244455B1 (https=) |
| JP (1) | JP2003514020A (https=) |
| AU (1) | AU780261B2 (https=) |
| CA (1) | CA2386954C (https=) |
| DE (1) | DE60042611D1 (https=) |
| WO (1) | WO2001035961A1 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6425881B1 (en) * | 1994-10-05 | 2002-07-30 | Nitrosystems, Inc. | Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
| AU7365900A (en) | 1999-09-08 | 2001-04-10 | Nitromed, Inc. | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| US6635273B1 (en) | 1999-10-29 | 2003-10-21 | Trustees Of Boston University | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US7708989B2 (en) * | 1999-10-29 | 2010-05-04 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US7537785B2 (en) | 1999-10-29 | 2009-05-26 | Nitromed, Inc. | Composition for treating vascular diseases characterized by nitric oxide insufficiency |
| US7235237B2 (en) | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US20050119270A1 (en) * | 2000-08-04 | 2005-06-02 | Mason R. P. | Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release |
| WO2002017898A2 (en) * | 2000-09-01 | 2002-03-07 | Sacks Meir S | Compositions and methods for inducing vasorelaxation |
| AU5939901A (en) * | 2000-10-27 | 2002-05-06 | Nitromed Inc | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US20110171296A1 (en) * | 2000-10-30 | 2011-07-14 | Biohit Oyj | Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine |
| FI121528B (fi) * | 2000-10-30 | 2010-12-31 | Biohit Oyj | Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa |
| AU2008201838B2 (en) * | 2001-05-02 | 2010-07-29 | Nicox S.A. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| CA2446064A1 (en) * | 2001-05-02 | 2002-11-07 | Nitromed, Inc. | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| IL159415A0 (en) | 2001-06-18 | 2004-06-01 | Noven Pharma | Enhanced drug delivery in transdermal systems |
| FR2832634A1 (fr) * | 2001-11-29 | 2003-05-30 | Univ Pasteur | Utilisation des isomeres l de derives aminoacides de l'hydroxyguanidine pour la production de no, compositions pharmaceutiques les contenant et utilisations pharmaceutiques |
| US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
| AUPS236902A0 (en) * | 2002-05-16 | 2002-06-13 | Northern Sydney Area Health Service | Composition and method for treating hypertension |
| US20040057983A1 (en) | 2002-09-25 | 2004-03-25 | David Schmidt | Biomolecular wearable apparatus |
| WO2004047837A2 (en) * | 2002-11-22 | 2004-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-blockers having antioxidant and nitric oxide-donor activity |
| US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
| CA2536975A1 (en) * | 2003-08-28 | 2005-03-17 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
| GB2423927A (en) * | 2003-08-29 | 2006-09-13 | Cotherix Inc | Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome |
| US20050209289A1 (en) * | 2004-03-16 | 2005-09-22 | Talarico Matthew T | Method for vascular dysregulation |
| WO2005107384A2 (en) * | 2004-03-31 | 2005-11-17 | Nitromed, Inc. | Methods for treating blood disorders with nitric oxide donor compounds |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| US7803838B2 (en) | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US20060014829A1 (en) * | 2004-07-16 | 2006-01-19 | Nitromed, Inc. | Methods for reducing hospitalizations related to heart failure |
| US7618594B2 (en) * | 2004-08-18 | 2009-11-17 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| AU2005277397B2 (en) | 2004-08-18 | 2011-08-25 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| JP4949661B2 (ja) * | 2004-09-21 | 2012-06-13 | 第一三共株式会社 | ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物 |
| US20060154959A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and carvedilol |
| US20080096915A1 (en) * | 2005-01-13 | 2008-04-24 | Greenberg Traurig LLP | Compositions for the treatment of metabolic disorders |
| US20070141174A1 (en) * | 2005-01-13 | 2007-06-21 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
| US20080306041A1 (en) * | 2005-01-21 | 2008-12-11 | Garvey David S | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use |
| WO2006128035A2 (en) * | 2005-05-26 | 2006-11-30 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
| AP2896A (en) * | 2005-05-31 | 2014-05-31 | Mylan Lab Inc | Compositions comprising nebivolol |
| GB0517838D0 (en) * | 2005-09-02 | 2005-10-12 | Henderson Morley Plc | Transdermal active principle delivery means |
| WO2007041681A2 (en) * | 2005-10-04 | 2007-04-12 | Nitromed, Inc. | Methods for treating respiratory disorders |
| US20070098791A1 (en) | 2005-10-31 | 2007-05-03 | Rekhi Gurvinder S | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride |
| US20070105817A1 (en) * | 2005-11-09 | 2007-05-10 | Jim Page | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
| AU2006322656B2 (en) * | 2005-12-09 | 2012-03-08 | Vectus Biosystems Limited | VIP fragments and methods of use |
| AU2007217980A1 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| EP2005949A1 (en) | 2006-03-13 | 2008-12-24 | Kaneka Corporation | Cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent |
| AU2007254283A1 (en) * | 2006-05-16 | 2007-11-29 | Nitromed, Inc. | Solid dosage formulations of hydralazine compounds |
| WO2007137980A1 (en) | 2006-05-29 | 2007-12-06 | Nicox S.A. | Nitrated heterocyclic compounds as endothelin receptor antagonist |
| US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
| US7862598B2 (en) | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US20090112197A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
| US20090110933A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
| US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
| US20080312241A1 (en) * | 2007-01-03 | 2008-12-18 | Gilead Sciences, Inc. | Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders |
| CN101229156B (zh) * | 2007-01-26 | 2010-07-07 | 鲁南制药集团股份有限公司 | 一种用于心血管系统疾病的药物组合物 |
| US20080193385A1 (en) * | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
| AU2008232413B2 (en) * | 2007-03-23 | 2013-09-19 | VERO Biotech LLC. | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| WO2008128832A1 (en) * | 2007-04-18 | 2008-10-30 | Nicox S.A. | Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome |
| US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
| US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
| US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| WO2009059271A1 (en) * | 2007-11-02 | 2009-05-07 | University Of Miami | Diagnosis and treatment of cardiac disorders |
| US7914743B2 (en) | 2008-01-28 | 2011-03-29 | Geno Llc | Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) |
| AU2009244790B2 (en) * | 2008-05-09 | 2013-09-12 | Duke University | Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
| US8602961B2 (en) * | 2008-05-15 | 2013-12-10 | Lifewave Products Llc | Apparatus and method of stimulating elevation of glutathione levels in a subject |
| US8607785B2 (en) | 2008-08-21 | 2013-12-17 | Geno Llc | Systems and devices for generating nitric oxide |
| JP5878866B2 (ja) | 2009-06-22 | 2016-03-08 | ゲノ エルエルシー | 一酸化窒素治療 |
| WO2011063335A1 (en) * | 2009-11-20 | 2011-05-26 | Geno Llc | Nitric oxide delivery system |
| CN104997746A (zh) * | 2015-08-24 | 2015-10-28 | 苏州艾伯特生物医药科技有限公司 | 一氧化氮供体型谷胱甘肽类化合物咀嚼片及应用 |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| CN110856713B (zh) * | 2018-08-23 | 2021-08-24 | 山东大学齐鲁医院 | 一种便携式治疗急性心衰发作的吸入式药物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2924005C2 (de) * | 1979-06-13 | 1984-07-05 | Sanol Schwarz-Monheim Gmbh, 4019 Monheim | Isosorbiddinitrat enthaltendes Mittel |
| US4584315A (en) * | 1981-11-16 | 1986-04-22 | The Upjohn Company | Method of treating ischemic states |
| US4584314A (en) * | 1983-11-25 | 1986-04-22 | Ciba-Geigy Corporation | Lactone derivative, process for the preparation thereof, and use thereof in pest control |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4868179A (en) | 1987-04-22 | 1989-09-19 | Cohn Jay N | Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate |
| DE68917946T2 (de) | 1988-01-29 | 1995-01-05 | Peter H Proctor | Haarwachstumanregung mit Nitroxyd und anderen Radikalen. |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5593694A (en) | 1991-10-04 | 1997-01-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Sustained release tablet |
| SK2895A3 (en) * | 1992-07-10 | 1995-07-11 | Boots Co Plc | Substituted 3-cyclobutene-1,2-diones, method of their preparation and pharmaceutical agents which containing thereof |
| US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5853751A (en) | 1993-06-23 | 1998-12-29 | Masiz; John J. | Molecular transdermal transport system |
| DE4410997A1 (de) | 1994-03-30 | 1995-10-26 | Isis Pharma Gmbh | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen |
| US5973011A (en) | 1994-03-30 | 1999-10-26 | Isis Pharma Gmbh | Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction |
| US5968983A (en) | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
| US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| JPH0959152A (ja) | 1995-08-18 | 1997-03-04 | Teisan Seiyaku Kk | 硝酸イソソルビド含有貼付剤 |
| DE19654895C2 (de) | 1996-02-07 | 2000-07-27 | Sanol Arznei Schwarz Gmbh | Detektionsverfahren |
| US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
| IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
| CA2248167C (en) | 1997-01-07 | 2004-02-03 | Teijin Limited | Patch containing isosorbide dinitrate |
| JP4136029B2 (ja) * | 1997-05-12 | 2008-08-20 | 帝國製薬株式会社 | 硝酸イソソルビド含有貼付剤 |
| IT1292426B1 (it) | 1997-06-27 | 1999-02-08 | Nicox Sa | Sali nitrati di ace-inibitori |
| IT1301759B1 (it) | 1998-06-19 | 2000-07-07 | Nicox Sa | Sali nitrati di farmaci antiipertensivi |
| US6117872A (en) | 1998-06-23 | 2000-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity |
| EP1235563A2 (en) * | 1998-08-26 | 2002-09-04 | Queen's University At Kingston | Use of anti(w)pressor agents for vascular remodeling in genital dysfunction |
| US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| AU7365900A (en) | 1999-09-08 | 2001-04-10 | Nitromed, Inc. | Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| US7235237B2 (en) | 1999-10-29 | 2007-06-26 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| US6635273B1 (en) | 1999-10-29 | 2003-10-21 | Trustees Of Boston University | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
-
2000
- 2000-10-27 US US09/697,317 patent/US6635273B1/en not_active Expired - Lifetime
- 2000-10-27 CA CA2386954A patent/CA2386954C/en not_active Expired - Fee Related
- 2000-10-27 DE DE60042611T patent/DE60042611D1/de not_active Expired - Lifetime
- 2000-10-27 AU AU14393/01A patent/AU780261B2/en not_active Ceased
- 2000-10-27 JP JP2001537954A patent/JP2003514020A/ja active Pending
- 2000-10-27 WO PCT/US2000/029528 patent/WO2001035961A1/en not_active Ceased
- 2000-10-27 EP EP00976651A patent/EP1244455B1/en not_active Expired - Lifetime
-
2003
- 2003-10-07 US US10/679,257 patent/US7556824B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514020A5 (https=) | ||
| CA2386954A1 (en) | Methods of treating vascular diseases characterized by nitric oxide insufficiency | |
| CN102091330B (zh) | 含有缬沙坦和nep抑制剂的药物组合物 | |
| EP0741567B1 (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
| JP2008525445A5 (https=) | ||
| EP0796617A1 (fr) | Utilisation de composés antiarythmiques dansla réduction de la mortalité post infarctus | |
| JP2002505676A (ja) | 微量投与療法 | |
| JP2007510618A (ja) | ピリドンの誘導体とその使用 | |
| EP1326604A2 (en) | Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| WO2007054975A1 (en) | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders | |
| TWI295173B (https=) | ||
| CN119300815A (zh) | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 | |
| JP2007529545A (ja) | ダウン症候群の治療法 | |
| EP0280593B1 (fr) | Composition à base d'acide aminé et de vitamines utilisable en thérapeutique cancérologique | |
| EP3922628A1 (fr) | Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline | |
| US20090326037A1 (en) | Medicinal Agent For Treating Viral Infections | |
| WO2024178621A1 (en) | Use of compounds in preventing and/or treating obesity or nafld | |
| WO2001074354A1 (en) | DIURETICS CONTAINING η-TOCOTRIENOL | |
| FR2760364A1 (fr) | Utilisation de composes antiarythmiques pour reduire la mortalite apres infarctus du myocarde | |
| WO2003094924A1 (en) | Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events | |
| JP2520244B2 (ja) | 弗素化ジアミノアルキン誘導体 | |
| EA001673B1 (ru) | Применение ингибиторов катехол-о-метилтрансферазы (комт) для производства лекарственного средства для профилактики сосудистых дисфункций при диабете | |
| EP0935964A1 (en) | Pharmaceutical compositions containing NSAIDs and piperine | |
| AU2006233237A1 (en) | A method of treatment and/or prophylaxis of ulcers |